Cargando…

Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations

Immune checkpoint inhibitors (ICBs) have revolutionized cancer treatment producing remarkable and durable responses for a range of malignancies. However, the additional modulation of immune response by ICBs may rarely cause immune-related infectious complications, including re-activation of latent t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anastasopoulou, Amalia, Ziogas, Dimitrios C., Samarkos, Michael, Kirkwood, John M., Gogas, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727332/ https://www.ncbi.nlm.nih.gov/pubmed/31484550 http://dx.doi.org/10.1186/s40425-019-0717-7

Ejemplares similares

Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies
por: Anastasopoulou, Amalia, et al.
Publicado: (2023)

Challenges in the treatment of melanoma with BRAF and MEK inhibitors in patients with sickle cell disease: case report and review of the literature
por: Diamantopoulos, Panagiotis T, et al.
Publicado: (2023)

The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature
por: Anastasopoulou, Amalia, et al.
Publicado: (2021)

When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report
por: Ziogas, Dimitrios C, et al.
Publicado: (2020)

Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers
por: Ziogas, Dimitrios C., et al.
Publicado: (2022)

Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report
por: Anastasopoulou, Amalia, et al.
Publicado: (2022)

Clinical considerations about the coexistence of melanoma and chronic lymphocytic leukemia in the era of targeted therapies, triggered by rare clinical scenarios. A case series and review of the literature
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2020)

Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy
por: Ziogas, Dimitrios C, et al.
Publicado: (2020)

Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond
por: Theocharopoulos, Charalampos, et al.
Publicado: (2021)

A case report of immune-mediated arthritis in a patient with cutaneous melanoma receiving checkpoint inhibition therapy
por: Papaxoinis, George, et al.
Publicado: (2020)

Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
por: Kassi, Eva, et al.
Publicado: (2019)

Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2022)

Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci et al
por: Ziogas, Dimitrios C, et al.
Publicado: (2021)

Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas
por: MANTA, ASPASIA, et al.
Publicado: (2023)

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
por: Ziogas, Dimitrios C., et al.
Publicado: (2023)

An overview of antibody–drug conjugates in oncological practice
por: Theocharopoulos, Charalampos, et al.
Publicado: (2020)

Diabetes insipidus: A rare endocrine complication of immune check point inhibitors: A case report and literature review
por: Angelousi, Anna, et al.
Publicado: (2022)

Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review
por: Ziogas, Dimitrios C., et al.
Publicado: (2021)

The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management
por: Girotra, Monica, et al.
Publicado: (2018)

Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations
por: Wang, Jun, et al.
Publicado: (2023)

Cutaneous angiosarcoma: A review of current evidence for treatment with checkpoint inhibitors
por: Guan, Lucy, et al.
Publicado: (2023)

Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid—A Retrospective, Monocentric Study
por: Schauer, Franziska, et al.
Publicado: (2022)

Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review
por: Sakellariou, Stratigoula, et al.
Publicado: (2021)

Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations
por: Perazella, Mark A, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors as a Treatment Option for Bladder Cancer: Current Evidence
por: Okobi, Tobechukwu J, et al.
Publicado: (2023)

Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections
por: Lu, Minya, et al.
Publicado: (2020)

Testosterone for the aging male; current evidence and recommended practice
por: Stanworth, Roger D, et al.
Publicado: (2008)

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
por: Hotta, Katsuyuki, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions
por: Sammarco, Enrico, et al.
Publicado: (2023)

Self-administration of epinephrine in children: a survey of current prescription practice and recommendations for improvement.
por: Hughes, J. L., et al.
Publicado: (2003)

The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events
por: Mytareli, Chrysoula, et al.
Publicado: (2023)

Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2
por: Psichogiou, Mina, et al.
Publicado: (2021)

Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
por: Kim, Bum Jun, et al.
Publicado: (2017)

Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known
por: Zheng, Caiyun, et al.
Publicado: (2023)

Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events
por: Grünwald, Viktor, et al.
Publicado: (2020)

Immune checkpoint inhibitor administration during pregnancy: a case series
por: Andrikopoulou, A., et al.
Publicado: (2021)

Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives
por: Zhang, Zhening, et al.
Publicado: (2020)

Therapy of Mucormycosis
por: Sipsas, Nikolaos V., et al.
Publicado: (2018)

1410. Isoniazid Therapy for Latent Tuberculosis Infection in Patients with Cancer Treated with Checkpoint Inhibitors Immunotherapy
por: Malek, Alexandre, et al.
Publicado: (2021)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
por: Zhuang, Junling, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m4e0nee3f0ju5nt36g7elv5s7l